118 related articles for article (PubMed ID: 34086522)
21. GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma.
Hu H; Li Z; Zhou Y; Zhang Y; Zhao L; Zhao W; Huang Y; Song X
Melanoma Res; 2019 Dec; 29(6):612-620. PubMed ID: 31305325
[TBL] [Abstract][Full Text] [Related]
22. Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma.
Ranieri JM; Wagner JD; Wiebke EA; Azuaje R; Smith ML; Wenck S; Daggy J; Coleman JJ
Plast Reconstr Surg; 2005 Apr; 115(4):1058-63. PubMed ID: 15793446
[TBL] [Abstract][Full Text] [Related]
23. Significance of survivin mRNA blood levels in patients with melanoma.
Samarkos M; Papaxoinis G; Athanasoula K; Benopoulou Ο; Bouros S; Anastasopoulou A; Diamantopoulos P; Gogas H; Mantzourani M
J BUON; 2018 Dec; 23(7):96-103. PubMed ID: 30722117
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion.
Berthier-Vergnes O; El Kharbili M; de la Fouchardière A; Pointecouteau T; Verrando P; Wierinckx A; Lachuer J; Le Naour F; Lamartine J
Br J Cancer; 2011 Jan; 104(1):155-65. PubMed ID: 21081927
[TBL] [Abstract][Full Text] [Related]
25. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma.
Hasselmann DO; Rappl G; Rössler M; Ugurel S; Tilgen W; Reinhold U
Oncol Rep; 2001; 8(1):115-8. PubMed ID: 11115581
[TBL] [Abstract][Full Text] [Related]
26. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
[TBL] [Abstract][Full Text] [Related]
27. Transcript levels of keratin 1/5/6/14/15/16/17 as potential prognostic indicators in melanoma patients.
Han W; Hu C; Fan ZJ; Shen GL
Sci Rep; 2021 Jan; 11(1):1023. PubMed ID: 33441834
[TBL] [Abstract][Full Text] [Related]
28. Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.
Mumford SL; Towler BP; Pashler AL; Gilleard O; Martin Y; Newbury SF
Biomolecules; 2018 Apr; 8(2):. PubMed ID: 29701682
[TBL] [Abstract][Full Text] [Related]
29. Characterization of long noncoding RNA and messenger RNA signatures in melanoma tumorigenesis and metastasis.
Wang S; Fan W; Wan B; Tu M; Jin F; Liu F; Xu H; Han P
PLoS One; 2017; 12(2):e0172498. PubMed ID: 28225791
[TBL] [Abstract][Full Text] [Related]
30. The prognostic potential of alternative transcript isoforms across human tumors.
Trincado JL; Sebestyén E; Pagés A; Eyras E
Genome Med; 2016 Aug; 8(1):85. PubMed ID: 27535130
[TBL] [Abstract][Full Text] [Related]
31. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
32. Circulating miR-146a expression as a non-invasive predictive biomarker for acute lymphoblastic leukemia.
Shahid S; Shahid W; Shaheen J; Akhtar MW; Sadaf S
Sci Rep; 2021 Nov; 11(1):22783. PubMed ID: 34815474
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.
Uesato Y; Sasahira N; Ozaka M; Sasaki T; Takatsuki M; Zembutsu H
PLoS One; 2020; 15(7):e0235623. PubMed ID: 32614932
[TBL] [Abstract][Full Text] [Related]
34. miRNA and mRNA expression profiling reveals potential biomarkers for metastatic cutaneous melanoma.
Wang J; Tao Y; Bian Q
Expert Rev Anticancer Ther; 2021 May; 21(5):557-567. PubMed ID: 33504224
[No Abstract] [Full Text] [Related]
35. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
36. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
37. Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer.
Cui Y; Wang W; Yao S; Qiu Z; Cong L
J Cancer Res Ther; 2020; 16(7):1641-1647. PubMed ID: 33565511
[TBL] [Abstract][Full Text] [Related]
38. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
39. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
40. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
Ono S; Oyama T; Lam S; Chong K; Foshag LJ; Hoon DS
Oncotarget; 2015 Mar; 6(9):7053-64. PubMed ID: 25749524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
